GSA Capital Partners LLP Has $507,000 Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL)

GSA Capital Partners LLP trimmed its holdings in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 59.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 89,299 shares of the biotechnology company’s stock after selling 131,561 shares during the quarter. GSA Capital Partners LLP owned about 0.11% of Anavex Life Sciences worth $507,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Atria Investments Inc acquired a new position in Anavex Life Sciences during the third quarter worth $76,000. SG Americas Securities LLC acquired a new position in Anavex Life Sciences during the second quarter worth $57,000. China Universal Asset Management Co. Ltd. increased its position in Anavex Life Sciences by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 16,309 shares of the biotechnology company’s stock worth $93,000 after buying an additional 6,366 shares during the last quarter. Fiduciary Alliance LLC increased its position in Anavex Life Sciences by 45.2% during the second quarter. Fiduciary Alliance LLC now owns 19,275 shares of the biotechnology company’s stock worth $80,000 after buying an additional 6,000 shares during the last quarter. Finally, EntryPoint Capital LLC grew its position in shares of Anavex Life Sciences by 371.1% in the first quarter. EntryPoint Capital LLC now owns 20,007 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 15,760 shares during the last quarter. 31.55% of the stock is owned by institutional investors and hedge funds.

Anavex Life Sciences Stock Performance

Shares of NASDAQ:AVXL opened at $8.24 on Wednesday. The company has a market cap of $698.75 million, a P/E ratio of -16.48 and a beta of 0.60. The stock’s 50-day moving average is $6.18 and its 200-day moving average is $5.44. Anavex Life Sciences Corp. has a 52-week low of $3.25 and a 52-week high of $10.45.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Anavex Life Sciences in a research report on Monday, November 4th.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.